PCV159 Analysis Of Stroke Statistics In Turkey  by Ozturk, Y et al.
A402  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  
Objectives: Pharmacogenetic (PG) algorithms of warfarin dosing have been proposed 
as potential improvement of anticoagulation control. Despite several randomized clin-
ical trials, the clinical benefit was not consistently proven. The objective of this study 
was to estimate the opportunity cost of introduction of warfarin PG testing into health 
system using an expected value of perfect information (EVPI) approach. MethOds: 
Previously developed cost-effectiveness model was employed to evaluate the PG 
algorithm-based warfarin dosing versus standard treatment. Differences in antico-
agulation control, in terms of percentage of time in therapeutic range (TTR), were used 
to simulate thromboembolic and haemorrhagic events. The outcomes were valued 
in quality-adjusted life-years (QALY) and 2014 cost. Uncertainty in the model param-
eters was assessed using probabilistic sensitivity analysis and EVPI was estimated 
at a threshold of 25,000 EUR/QALY gained. Results: In the base case, where price 
of PG test was 40 EUR, the ICER of genotype-guided treatment was 8.146 EUR/QALYg 
compared to the standard treatment. When uncertainty about clinical efficacy was 
examined, ICER ranged from approximately 1.000 EUR/QALYg to dominated strategy. 
Another important factor was the price of PG test. In the base case, the treatment 
using PG algorithm had highest expected net-benefit with opportunity loss surround-
ing uncertainty about clinical efficacy of 2.9 EUR per treated patient. Conversely, 
increasing the cost of PG test by 3 times, to 120 EUR, resulted in the highest total 
expected net-benefit for standard treatment. Selecting the genotype-guided treat-
ment instead of standard therapy would result in opportunity loss of 47.2 EUR, while 
EVPPI for standard treatment was 0.82 EUR. cOnclusiOns: The price of PG test is 
an important factor about decision of warfarin PG introduction into health system 
or investment into additional clinical trials. The smaller cost of PG test means lower 
opportunity cost, consequentially future research should not have important impact 
on economic aspect of decision.
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Objectives: In the prescription of pharmaceutical therapies for the chronic dis-
eases there is the responsibility both the hospital specialist doctor and the one 
territorial. A responsibility that can not be distinguished by the enterprise informa-
tion systems. Purpose of the study is the development of an informatic framework 
to implement specific training plans on the hospital’s doctors in order to reduce 
the prescription of the ACE-inhibitors compared to the ARBs. MethOds: It has 
been used 2014 data of pharmaceutical prescriptions of ACE-inhibitors and ARBs, 
outpatient specialistic for cardiology visits, of hospital admissions by the Polyclinic 
of Modena, in an observational cohort study of record linkage, identifying for each 
outpatient service and of hospitalization the pharmaceutical prescription 30 days 
later 60 days prior the hospital activity. Results: It has been analysed 3,5 Billion 
outpatient prescriptions and 27.529 hospitalizations, noting that naive patients 
have received 51% of ACE-inhibitors, 64% of patients has changed his own ther-
apy from ARBs to ACE-inhibitors, while 28% has a stable therapy after cardiology 
visits. cOnclusiOns: The model has allowed to distinguish the pharmaceutical 
therapy accomplished by the hospital’s doctors compared to the one of the doc-
tors of general medicine, highlighting also the therapies changed by the doctors of 
general medicine, in the absence of a focused informative system. The new data 
framework will support a face to face training.
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Objectives: To investigate whether usage patterns differ for different indications 
of angiotensin converting enzyme inhibitors (ACE-inhibitors). MethOds: Patients 
older than 45 years who started ACE-inhibitor treatment between January 2007 
and January 2014 were selected in the Clinical Practice Research Datalink (CPRD). 
Indications for ACE-inhibitor treatment were retrieved from the medical records. 
Stratified by indication we distinguished between continuous use, discontinued 
use, switch to an alternative drug, and restart, considering a 6 months’ time interval 
between two prescription periods. Five-years persistence rates among the differ-
ent indications were calculated using the Kaplan-Meier method and compared by 
the log-rank test. Results: In total 276,977 patients initiating ACE-inhibitors were 
identified with the following indications: hypertension (56.9 %), myocardial infarc-
tion (4.3%), renal failure (3.7%), heart failure (1.6%), combinations of them (17%) and 
none of the above (16.5%). Five-year persistence rates ranged from 44.1% for renal 
failure to 68.9% for myocardial infarction (p< 0.0001). Heart failure and renal failure 
patients used ACE-inhibitors for the shortest period of time (average 21.8 and 21.9 
months, respectively). Within the discontinuation group the percentages of switch-
ers ranged from 35.9% for renal failure to 53.9% for hypertension (61.0% switched to 
an angiotensin II-receptor blocker) and for the restarter group ranged from 15.0% for 
heart failure to 18.1% for the group without indication retrieved. cOnclusiOns: 
Dependent on the indication the rates of ACE-inhibitor discontinuation differ. 
Patients with renal failure are most likely to discontinue treatment.
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Objectives: Japan has universal health coverage, and, regulations concerning med-
ical reimbursements are loose in the prescription, with physicians having a high 
degree of discretion in prescriptions. There is no upper limit or reference pricing, and 
as both physicians and patients prefer brand drugs, there has been a lack of progress 
a patient with stroke lives and which factors most influence survival in stroke 
in Turkey. MethOds: Based on Elixhauser Comorbidity Index, data for patients 
diagnosed at least with stroke or 17 chronic diseases such as hypertension, diabe-
tes, heart diseases were collected from Turkish SocSecurity Institution database 
between 2008 and 2013. Then with simple random sampling method, a sample of 
2,113 ischemic stroke and 155 hemorrhagic stroke patients were selected. Two Cox 
regression models were run to identify which factors impact the survival years and 
how much they reduce survival for each stroke type. Finally survival months were 
calculated. Results: Among dead patients, a patient with stroke lived less than a 
year on average. 14%, 11%, 11% and 14% percent of stroke patients died 1-2 years, 2-3 
years, 3-4 years and more than 4 years respectively. In the first model the average 
survival month for an ischemic stroke patient was 35. Age and gender didn’t change 
survival months statistically. Hypertension, diabetes, heart disease and nervous 
system diseases reduced survival months by 4, 12, 7 and 9 months respectively with 
95% confidence level. In the second model a hemorrhagic patient lived 39 months 
on average. A patient younger than 55 experienced 10 months longer lives than a 
patient over 55. Gender again didn’t incorporate any chance to survival. In addi-
tion, a patient with no hypertension and heart disease enjoyed 24 and 19 months 
longer lives respectively. cOnclusiOns: In Turkey, the chance of living longer for 
ischemic stroke patients drops if the patients were diagnosed with hypertension, 
diabetes, heart disease or nervous system disease. Older patients with hemorrhagic 
stroke lived less, hypertension and heart disease adversely affected survival months.
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Objectives: Stroke is a severe disease that leads one of the main causes of death and 
disability affecting approximately 15 million people worldwide. This study aims at 
analyzing summary statistics of stroke in Turkey. MethOds: Data was collected for 
the patients diagnosed with stroke from Turkish Social Security Institution database 
between 2008 and 2013. Prevalence, gender and age distribution of the disease were 
computed. Then basic statistics of each type of the disease were analyzed. Results: 
Between 2008 and 2013 1.9 million people were diagnosed with stroke. Among those 
patients, 44% and 56% were males and females respectively. Over 6 years roughly 400 
thousand diagnosed patients died and as of December 31, 2013 nearly 1.5 million peo-
ple had stroke with a prevalence of 2%. The prevalence for females (2.2%) was higher 
than that of males (1.7%), higher for 0-74 age group but lower for 75+. The prevalence 
rises as age increases, 75+ population had 62, 12, 2 times higher risk of having stroke 
compared to 0-25, 35-44 and 55-64 age groups. In our study, stroke is divided into four 
subgroups: ischemic stroke, sequels, hemorrhagic stroke and unknown stroke. 84% 
of all cases was recorded as ischemic stroke (getting the largest share parallel to the 
literature), 9% as sequels, 5% hemorrhagic stroke and only 2% is unknown stroke. 
While 0-44 age group aggregated 13.2% of all ischemic stroke patients, the figure hiked 
28.1% for hemorrhagic stroke patients. cOnclusiOns: Stroke is one of the leading 
causes of death in Turkey and the prevalence in 2013 totaled 2% of Turkish population. 
Considering that Turkey is aging rapidly in spite of having a young population, the 
number of cases with stroke will grow in near future, signaling higher stroke related 
death figures if no action is taken.
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Objectives: Coronary heart disease (CHD) treatment has seen significant improve-
ments due to new health technologies (HT) in interventional cardiology. Health sys-
tems (HS) adopt new HT at different speed and use rates, which may become more 
apparent when contrasting between HS with distinct features. We characterized and 
compared the ability of the HS of United States (US) and Portugal (PT) to access and 
use new HT to treat CHD. MethOds: A total of 30 HT between January 1980 and 
February 2015, including medical devices and active substances, were identified by 
experts and reviewed. Approval/commercialization dates of the first medical devices 
models and active substances brands were abstracted using databases at the local 
regulatory agencies and complemented with other sources of information when nec-
essary. Differences between dates were used for comparison between countries. We 
additionally performed an extensive literature review and retrieved information on 
use trends of these HT in PT versus US. Results: Most medical devices reviewed were 
approved earlier in PT than in US (median time difference: 27 months), whereas drugs 
were more readily available in US (median time difference: 61 months). Furthermore, 
while all HT are currently approved in PT, the drug-eluting balloon, Nicorandil and 
Ivabradine lack approval in US. Utilization patterns vary across devices but evidence 
suggests that adoption in PT is sometimes deferred from approval and that the US 
generally reaches similar or higher utilization rates than PT. Commercialization of 
drugs in PT was delayed by a median of 65 months from approval. cOnclusiOns: 
Regulatory mechanisms of approval and price controls are determinant in the type of 
HT available. However, other factors appear to play an important role in the diffusion 
of new HT. Differences in use could be explored for mutual benefit for assessing and 
monitoring safety and cost-effectiveness of HT between the two HS.
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